{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:54:48Z","timestamp":1781027688289,"version":"3.54.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.clinme.2024.100229","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T21:56:52Z","timestamp":1721253412000},"page":"100229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pure red cell aplasia secondary to erythropoietin therapy"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-2724","authenticated-orcid":false,"given":"Gwenno Mair","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulfattah A","family":"Alejmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinme.2024.100229_bib0001","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2215\/CJN.02440607","article-title":"Pure red cell aplasia induced by erythropoiesis-stimulating agents","volume":"3","author":"Pollock","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinme.2024.100229_bib0002","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa040528","article-title":"Pure red-cell aplasia and epoetin therapy","volume":"351","author":"Bennett","year":"2004","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clinme.2024.100229_bib0003","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1097\/01.ASN.0000140219.28618.9F","article-title":"Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin prodcuts: recommendations for minimization of risk","volume":"15","author":"Cournoyer","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinme.2024.100229_bib0004","doi-asserted-by":"crossref","first-page":"e05554","DOI":"10.1002\/ccr3.5554","article-title":"Cutaneous allergic reaction correlates with anti-erythropoietin antibodies in dialysis patient developing pure red cell aplasia","volume":"10","author":"Badiu","year":"2022","journal-title":"Clin Case Rep"},{"issue":"9423","key":"10.1016\/j.clinme.2024.100229_bib0005","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0140-6736(04)16302-2","volume":"363","author":"Verhelst","year":"2004","journal-title":"The Lancet"},{"issue":"15","key":"10.1016\/j.clinme.2024.100229_bib0006","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood.2021010898","article-title":"How I manage acquired pure red cell aplasia in adults","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clinme.2024.100229_bib0007","article-title":"Case report: Dynamic antibody monitoring in a case of anti-recombinant human erythropoietin-mediated pure red cell aplasia with prolonged course after kidney transplantation","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824054149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824054149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T09:53:00Z","timestamp":1724493180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824054149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1470211824054149"],"URL":"https:\/\/doi.org\/10.1016\/j.clinme.2024.100229","relation":{},"ISSN":["1470-2118"],"issn-type":[{"value":"1470-2118","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pure red cell aplasia secondary to erythropoietin therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinme.2024.100229","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100229"}}